March 29 : Insilico Medicine said on Sunday it is partnering with Eli Lilly in a deal worth up to $2.75 billion, expanding an existing collaboration on AI-powered drug discovery. Lilly will use Insilico's AI engine and receive an exclusive worldwide license for the development, manufacturing, and commercialization of certain oral treatments currently in preclinical development. Under the terms of the agreement, Insilico is eligible to receive a $115 million upfront payment, followed by